LILRA4 and cutaneous lupus erythematosus: The monoclonal antibody VIB7734, directed against immunoglobulin-like Transcript 7 (ILT7), has shown efficacy in depleting circulating and tissue-resident pDCs in patients with cutaneous lupus erythematosus, attenuating local type I interferon activity and improving clinical outcomes [238, 239].